Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Treatment decision to Radium-223 needs to be made independent from and before patient enrollment in the study
Histologically or cytologically confirmed castration resistant adenocarcinoma of the prostate with bone metastases
Signed informed consent
You may not be if
Previously treated with Radium-223 for any reason
Currently treated in clinical trials including other Radium-223 studies
Planned for the systemic concomitant use of other radiopharmaceuticals for treatment of prostate cancer or for other use
Clareo Health | Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
